Biomarker discovery from high-throughput transcriptomic data is crucial for advancing precision medicine. However, existing methods often neglect gene-gene regulatory relationships and lack stability across datasets, leading to conflation of spurious correlations with genuine causal effects. To address these issues, we develop a causal graph neural network (Causal-GNN) method that integrates causal inference with multi-layer graph neural networks (GNNs). The key innovation is the incorporation of causal effect estimation for identifying stable biomarkers, coupled with a GNN-based propensity scoring mechanism that leverages cross-gene regulatory networks. Experimental results demonstrate that our method achieves consistently high predictive accuracy across four distinct datasets and four independent classifiers. Moreover, it enables the identification of more stable biomarkers compared to traditional methods. Our work provides a robust, efficient, and biologically interpretable tool for biomarker discovery, demonstrating strong potential for broad application across medical disciplines.

Integrating multi-omics data, such as DNA methylation, mRNA expression, and microRNA (miRNA) expression, offers a comprehensive view of the biological mechanisms underlying disease. However, the high dimensionality and complex interactions among omics layers present major challenges for predictive modeling. We propose Multi-Omics integration with Tree-generated Graph Neural Network (MOTGNN), a novel and interpretable framework for binary disease classification. MOTGNN employs eXtreme Gradient Boosting (XGBoost) to perform omics-specific supervised graph construction, followed by modality-specific Graph Neural Networks (GNNs) for hierarchical representation learning, and a deep feedforward network for cross-omics integration. On three real-world disease datasets, MOTGNN outperforms state-of-the-art baselines by 5-10% in accuracy, ROC-AUC, and F1-score, and remains robust to severe class imbalance (e.g., 87.2% vs. 33.4% F1 on imbalanced data). The model maintains computational efficiency through sparse graphs (2.1-2.8 edges per node) and provides built-in interpretability, revealing both top-ranked biomarkers and the relative contributions of each omics modality. These results highlight MOTGNN's potential to improve both predictive accuracy and interpretability in multi-omics disease modeling.

Multimodal machine learning integrating histopathology and molecular data shows promise for cancer prognostication. We systematically reviewed studies combining whole slide images (WSIs) and high-throughput omics to predict overall survival. Searches of EMBASE, PubMed, and Cochrane CENTRAL (12/08/2024), plus citation screening, identified eligible studies. Data extraction used CHARMS; bias was assessed with PROBAST+AI; synthesis followed SWiM and PRISMA 2020. Protocol: PROSPERO (CRD42024594745). Forty-eight studies (all since 2017) across 19 cancer types met criteria; all used The Cancer Genome Atlas. Approaches included regularised Cox regression (n=4), classical ML (n=13), and deep learning (n=31). Reported c-indices ranged 0.550-0.857; multimodal models typically outperformed unimodal ones. However, all studies showed unclear/high bias, limited external validation, and little focus on clinical utility. Multimodal WSI-omics survival prediction is a fast-growing field with promising results but needs improved methodological rigor, broader datasets, and clinical evaluation. Funded by NPIC, Leeds Teaching Hospitals NHS Trust, UK (Project 104687), supported by UKRI Industrial Strategy Challenge Fund.

We present BioLangFusion, a simple approach for integrating pre-trained DNA, mRNA, and protein language models into unified molecular representations. Motivated by the central dogma of molecular biology (information flow from gene to transcript to protein), we align per-modality embeddings at the biologically meaningful codon level (three nucleotides encoding one amino acid) to ensure direct cross-modal correspondence. BioLangFusion studies three standard fusion techniques: (i) codon-level embedding concatenation, (ii) entropy-regularized attention pooling inspired by multiple-instance learning, and (iii) cross-modal multi-head attention -- each technique providing a different inductive bias for combining modality-specific signals. These methods require no additional pre-training or modification of the base models, allowing straightforward integration with existing sequence-based foundation models. Across five molecular property prediction tasks, BioLangFusion outperforms strong unimodal baselines, showing that even simple fusion of pre-trained models can capture complementary multi-omic information with minimal overhead.

Messenger RNA (mRNA)-based vaccines are accelerating the discovery of new drugs and revolutionizing the pharmaceutical industry. However, selecting particular mRNA sequences for vaccines and therapeutics from extensive mRNA libraries is costly. Effective mRNA therapeutics require carefully designed sequences with optimized expression levels and stability. This paper proposes a novel contextual language model (LM)-based embedding method: mRNA2vec. In contrast to existing mRNA embedding approaches, our method is based on the self-supervised teacher-student learning framework of data2vec. We jointly use the 5' untranslated region (UTR) and coding sequence (CDS) region as the input sequences. We adapt our LM-based approach specifically to mRNA by 1) considering the importance of location on the mRNA sequence with probabilistic masking, 2) using Minimum Free Energy (MFE) prediction and Secondary Structure (SS) classification as additional pretext tasks. mRNA2vec demonstrates significant improvements in translation efficiency (TE) and expression level (EL) prediction tasks in UTR compared to SOTA methods such as UTR-LM. It also gives a competitive performance in mRNA stability and protein production level tasks in CDS such as CodonBERT.

Generating rationales that justify scoring decisions has been a promising way to facilitate explainability in automated scoring systems. However, existing methods do not match the accuracy of classifier-based methods. Plus, the generated rationales often contain hallucinated information. To address these issues, we propose a novel framework capable of generating more faithful rationales and, more importantly, matching performance with classifier-based black-box scoring systems. We first mimic the human assessment process by querying Large Language Models (LLMs) to generate a thought tree. We then summarise intermediate assessment decisions from each thought tree path for creating synthetic rationale data and rationale preference data. Finally, we utilise the generated synthetic data to calibrate LLMs through a two-step training process: supervised fine-tuning and preference optimization. Extensive experimental results demonstrate that our framework achieves a 38% assessment performance improvement in the QWK score compared to prior work while producing higher-quality rationales, as recognised by human evaluators and LLMs. Our work sheds light on the effectiveness of performing preference optimization using synthetic preference data obtained from thought tree paths.

Determining interactions between entities and the overall organization and clustering of nodes in networks is a major challenge when analyzing biological and social network data. Here we extend the Indian Buffet Process (IBP), a nonparametric Bayesian model, to integrate noisy interaction scores with properties of individual entities for inferring interaction networks and clustering nodes within these networks. We present an application of this method to study how microR-NAs regulate mRNAs in cells. Analysis of synthetic and real data indicates that the method improves upon prior methods, correctly recovers interactions and clusters, and provides accurate biological predictions.

The pharmaceutical Research and development (R&D) process is lengthy and costly, taking nearly a decade to bring a new drug to the market. However, advancements in biotechnology, computational methods, and machine learning algorithms have the potential to revolutionize drug discovery, speeding up the process and improving patient outcomes. The COVID-19 pandemic has further accelerated and deepened the recognition of the potential of these techniques, especially in the areas of drug repurposing and efficacy predictions. Meanwhile, non-small molecule therapeutic modalities such as cell therapies, monoclonal antibodies, and RNA interference (RNAi) technology have gained importance due to their ability to target specific disease pathways and/or patient populations. In the field of RNAi, many experiments have been carried out to design and select highly efficient siRNAs. However, the established patterns for efficient siRNAs are sometimes contradictory and unable to consistently determine the most potent siRNA molecules against a target mRNA. Thus, this paper focuses on developing machine learning models based on the cheminformatics representation of the nucleotide composition (i.e. AUTGC) of siRNA to predict their potency and aid the selection of the most efficient siRNAs for further development. The PLS (Partial Least Square) and SVR (Support Vector Regression) machine learning models built in this work outperformed previously published models. These models can help in predicting siRNA potency and aid in selecting the best siRNA molecules for experimental validation and further clinical development. The study has demonstrated the potential of AI/machine learning models to help expedite siRNA-based drug discovery including the discovery of potent siRNAs against SARS-CoV-2.

We provide partial implementations of von Neumann's universal constructor and universal copier, starting out with three types of simple building blocks using minimal assumptions. Using the same principles, we also construct Turing machines. Combining both, we arrive at a proposal for a self-replicating Turing machine. Our construction allows for mutations if desired, and we give a simple description language.

Predicting RNA (ribonucleic acid) structures may help accelerate the discovery and development of new drugs to treat diseases and disorders. A new Stanford study published in Science uses artificial intelligence (AI) machine learning to predict RNA structures with state-of-the-art performance results. "Few RNA structures are known, however, and predicting them computationally has proven challenging," wrote the Stanford scientists. "We introduce a machine learning approach that enables identification of accurate structural models without assumptions about their defining characteristics, despite being trained with only 18 known RNA structures." In molecular biology, RNA (ribonucleic acid) is involved in many important cellular functions.